| アブストラクト | BACKGROUND/OBJECTIVE: Signals from the FDA Adverse Event Reporting System (AERS) and pre-clinical and human pancreata obtained from organ donors have suggested that incretin-based therapies used to treat type 2 diabetes mellitus, such as glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, may increase the risk of acute pancreatitis (AP) and pancreatic cancer (PC). However, data from observational studies and randomized trials have been conflicting. We conducted a literature review to identify and summarize all observational data published assessing the pancreatic safety of incretins. METHODS: Searches were conducted in MEDLINE via PubMed and Embase using the key terms for the time period of 1 January 2005, to 12 February 2014. A total of 180 articles were screened in abstract form and 49 were subsequently reviewed in full text for inclusion. Data from 12 articles are included in this report. FINDINGS: Data from the FDA AERS database suggest increased risk of AP and PC with GLP-1 receptor agonist and DPP-4 inhibitor use. These findings are not supported by population-based observational studies for either AP or PC; however, studies assessing the relationship between PC and incretin-based therapies are limited. CONCLUSIONS: Current evidence is conflicting and inadequate to conclude whether use of incretin-based therapies increases the risk of AP and PC. Further studies, with the ability to provide long term follow-up, are needed. |
|---|
| ジャーナル名 | Current medical research and opinion |
|---|
| Pubmed追加日 | 2014/9/3 |
|---|
| 投稿者 | Suarez, Elizabeth A; Koro, Carol E; Christian, Jennifer B; Spector, Alicia D; Araujo, Andre B; Abraham, Sybil |
|---|
| 組織名 | Department of Epidemiology, New England Research Institutes Inc. , Watertown, MA;, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/25180611/ |
|---|
